MHRA Clarifies Registration Duties for Medical Devices Across Great Britain and Northern Ireland
The MHRA’s registration guidance draws a hard line around when a medical device, an in vitro diagnostic, a system or procedure pack, or a custom-made device must be entered on the agency’s register before it can enter the market. The rules now read less like a general advisory and more like an operating manual for manufacturers navigating two different regulatory systems: one for Great Britain and another for Northern Ireland. The practical consequence is simple. If the device is not registered where registration is required, it should not be placed on the market.
The guidance also makes plain that registration is an administrative requirement, not a mark of product endorsement. A manufacturer cannot imply MHRA approval, accreditation, or certification because a product appears on the register. Claims of that kind, including the use of MHRA logos on packaging, instructions for use, or commercial material, are prohibited. For companies that rely on regulatory credibility as part of their market positioning, that boundary is not cosmetic; it defines how registration data may be used in the commercial setting.
Great Britain Registration Starts Before First Supply
For Great Britain, the registration obligation attaches before first supply. The guidance specifies that manufacturers, refurbishers, relabellers, and suppliers of system or procedure packs must register relevant devices with the MHRA before they are placed on the market in England, Wales, or Scotland. The obligation covers Class I, IIa, IIb, and III devices, custom-made devices, and IVDs, including IVDs undergoing performance evaluation. In regulatory terms, the trigger is not merely manufacture but the act of making the device available for use, whether free of charge or for payment.
The distinction between placing on the market and putting into service matters because the two do not always occur together. Placing on the market refers to the first making available of a device on the GB market. Putting into service refers to the point at which the device reaches the final user. In most ordinary commercial channels, a device will do both. A hospital that manufactures and uses its own device on site may fall into the narrower category of putting into service only. In those limited cases, MHRA registration is encouraged but not required.
This is where regulatory precision meets clinical reality. Hospitals, laboratories, and manufacturers that build bespoke systems for local use may assume that absence of commercial distribution removes the registration burden. The guidance rejects that assumption by separating on-site use from market placement and by requiring manufacturers to assess which pathway applies before any device moves into service.
A UK Responsible Person Is Required for Overseas Manufacturers
Manufacturers based outside the UK must appoint a single UK Responsible Person to assume the duties associated with MHRA registration. The guidance places that person at the center of the compliance structure for foreign manufacturers selling into Great Britain. That requirement consolidates responsibility into one named entity rather than dispersing it across multiple intermediaries, which helps the regulator track accountability when products are distributed across the GB market.
A separate operational point appears in the guidance: former Great Britain-based Authorised Representatives who did not update their role to UK Responsible Person by 30 March 2026 now have closed DORS accounts. The implication is that transition arrangements are not open-ended. Registrants had a fixed window to align with the revised structure, and the agency has now closed off legacy access for those who did not complete the change.
Registration Does Not End When Supply Stops Overnight
Discontinuation is treated with more nuance than a simple removal from a product catalog. If a device is discontinued and no further product is placed on the market, registration is no longer required from the point at which the device is no longer made available on the GB market. The post-market obligations do not disappear, however. Surveillance and vigilance duties continue for devices already in circulation, which preserves the regulatory chain after commercial supply ends.
This arrangement has direct operational consequences for manufacturers managing portfolio wind-downs. A dormant registration tied to an unavailable product should not remain on the register indefinitely, but safety follow-up does not stop when sales do. The guidance directs users to the device management instructions in the reference guide when unregistering devices that are no longer marketed.
Northern Ireland Now Follows a Different Registration Path
Northern Ireland operates under a different set of rules, and the guidance separates that market from Great Britain with unusual clarity. For custom-made devices, registration with the MHRA is required when the device is first placed on the Northern Ireland market. Manufacturers based outside Northern Ireland or the EU must appoint an EU- or Northern Ireland-based Authorised Representative if they intend to place devices there. Great Britain manufacturers face the same requirement.
A major change sits in the 28 May 2026 rule shift. From that date, all medical devices other than custom-made devices must be registered in EUDAMED before placement on the EU and Northern Ireland markets, and MHRA registration is no longer required for those devices. Custom-made devices remain outside EUDAMED registration and continue to require MHRA registration under the Northern Ireland protocol regulations. For manufacturers, this creates a split pathway: one route for most devices through the European database, and a separate route for custom-made devices through the MHRA.
The effect on compliance planning is immediate. Regulatory teams now have to determine whether a product is custom-made, whether it is subject to EUDAMED, and whether a Northern Ireland or EU-based representative is in place. A single device can no longer be treated as if it were entering a uniform UK market. The registration route depends on geography, device type, and the legal status of the manufacturer or representative.
Fees, Data Accuracy, and Continued Scrutiny
The updated guidance also keeps fees in view. Any change to a registration may trigger a statutory fee, and the agency continues to require that all registered information remain accurate and current. The annual fee structure has been revised repeatedly across 2025 and 2026, and the page now reflects the newer fee arrangements. Separate updates have also clarified the handling of organization name and address changes, Letters of Designation, and annual fee deadlines.
Behind the fee language sits a broader regulatory principle: registration data are not passive records. They are validation tools, and the MHRA may request technical documentation to confirm that a product complies with the Medical Devices Regulations. That means the register is not simply a filing cabinet; it is part of the enforcement machinery.
For manufacturers, the legal message is direct. Register before market entry where required. Keep the registration current. Do not treat registration as endorsement. And do not assume that a product can move across Great Britain, Northern Ireland, and the EU under one set of rules when the guidance now divides those markets with increasing specificity.
The unanswered operational issue is not whether registration matters, but how quickly manufacturers can adapt their compliance systems as the Great Britain and Northern Ireland pathways continue to diverge.